• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期非小细胞肺癌生存的预后因素:1052例患者的单因素和多因素分析,包括递归划分和合并算法。欧洲肺癌工作组。

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

作者信息

Paesmans M, Sculier J P, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P

机构信息

Unité de Biostatistique, Institut Jules Bordet, Bruxelles, Belgium.

出版信息

J Clin Oncol. 1995 May;13(5):1221-30. doi: 10.1200/JCO.1995.13.5.1221.

DOI:10.1200/JCO.1995.13.5.1221
PMID:7738625
Abstract

PURPOSE

This study attempted to determine the prognostic value for survival of various pretreatment characteristics in patients with nonresectable non-small-cell lung cancer in the context of more than 10 years of experience of a European Cooperative Group.

PATIENTS AND METHODS

We included in the analysis all eligible patients (N = 1,052) with advanced non-small-cell lung cancer registered onto one of seven trials conducted by the European Lung Cancer Working Party (ELCWP) during one decade. The patients were treated by chemotherapy regimens based on platinum derivatives. We prospectively collected 23 variables and analyzed them by univariate and multivariate methods.

RESULTS

The global estimated median survival time was 29 weeks, with a 95% confidence interval of 27 to 30 weeks. After univariate analysis, we applied two multivariate statistical techniques. In a Cox regression model, the selected explanatory variables were disease extent, Karnofsky performance status, WBC and neutrophil counts, metastatic involvement of skin, serum calcium level, age, and sex. These results were confirmed by application of recursive partitioning and amalgamation algorithms (RECPAM), which led to classification of the patients into four homogeneous subgroups.

CONCLUSION

We confirmed by our analysis the role of well-known independent prognostic factors for survival, but also identified the effect of the neutrophil count, rarely studied, with the use of two methods: a classical Cox regression model and a RECPAM analysis. The classification of patients into the four subgroups we obtained needs to be validated in other series.

摘要

目的

在欧洲合作组超过10年经验的背景下,本研究试图确定不可切除的非小细胞肺癌患者各种预处理特征对生存的预后价值。

患者与方法

我们纳入分析了在十年期间登记参加欧洲肺癌工作组(ELCWP)开展的七项试验之一的所有符合条件的晚期非小细胞肺癌患者(N = 1052)。患者接受基于铂类衍生物的化疗方案治疗。我们前瞻性收集了23个变量,并通过单变量和多变量方法进行分析。

结果

总体估计中位生存时间为29周,95%置信区间为27至30周。单变量分析后,我们应用了两种多变量统计技术。在Cox回归模型中,选定的解释变量为疾病范围、卡诺夫斯基功能状态、白细胞和中性粒细胞计数、皮肤转移累及情况、血清钙水平、年龄和性别。应用递归划分与合并算法(RECPAM)证实了这些结果,该算法将患者分为四个同质亚组。

结论

我们通过分析证实了已知的生存独立预后因素的作用,同时还通过经典的Cox回归模型和RECPAM分析这两种方法确定了很少研究的中性粒细胞计数的影响。我们获得的将患者分为四个亚组的分类需要在其他系列中进行验证。

相似文献

1
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.晚期非小细胞肺癌生存的预后因素:1052例患者的单因素和多因素分析,包括递归划分和合并算法。欧洲肺癌工作组。
J Clin Oncol. 1995 May;13(5):1221-30. doi: 10.1200/JCO.1995.13.5.1221.
2
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.化疗反应对晚期非小细胞肺癌患者的进一步生存具有预测价值:欧洲肺癌工作组的10年经验
Eur J Cancer. 1997 Dec;33(14):2326-32. doi: 10.1016/s0959-8049(97)00325-0.
3
Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years.小细胞肺癌患者的预后因素:对连续4项前瞻性试验中纳入的763例患者进行分析,最短随访时间为5年。
Cancer. 2000 Aug 1;89(3):523-33. doi: 10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6.
4
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.对于接受化疗和放疗的Ⅲ期不可切除非小细胞肺癌,采用新的分期分类能更好地预测生存率。
Lung Cancer. 2004 Sep;45(3):339-48. doi: 10.1016/j.lungcan.2004.02.016.
5
Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation.晚期非小细胞肺癌患者的预后因素:单因素和多因素分析,包括递归划分与合并
Lung Cancer. 1996 Aug;15(1):67-77. doi: 10.1016/0169-5002(96)00571-5.
6
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.东亚晚期非小细胞肺癌患者中吉非替尼抗肿瘤活性的预测因素
J Thorac Oncol. 2006 Jul;1(6):520-5.
7
[Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party].[晚期非小细胞支气管癌的预后因素:欧洲肺癌工作组的经验]
Rev Mal Respir. 1997 Dec;14(6):445-9.
8
Small-cell carcinoma of the lung: derivation of a prognostic staging system.肺小细胞癌:一种预后分期系统的推导
J Clin Oncol. 1991 Sep;9(9):1639-49. doi: 10.1200/JCO.1991.9.9.1639.
9
Prognostic factors for survival in advanced non-small cell lung cancer.晚期非小细胞肺癌生存的预后因素
J Med Assoc Thai. 2004 Sep;87(9):1056-64.
10
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.广泛期非小细胞肺癌的生存决定因素:西南肿瘤协作组的经验
J Clin Oncol. 1991 Sep;9(9):1618-26. doi: 10.1200/JCO.1991.9.9.1618.

引用本文的文献

1
Prognostic Value of the Noble and Underwood Score in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection.诺布尔和安德伍德评分在接受手术切除的非小细胞肺癌患者中的预后价值。
J Cancer. 2024 Oct 14;15(19):6185-6195. doi: 10.7150/jca.101320. eCollection 2024.
2
Multivariate analysis of prognostic factors in patients with lung cancer.肺癌患者预后因素的多变量分析
Front Oncol. 2023 Feb 22;13:1022862. doi: 10.3389/fonc.2023.1022862. eCollection 2023.
3
Co-Mutation Status Association with Clinical Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer.
共同突变状态与EGFR突变型非小细胞肺癌患者临床结局的关联
Cancers (Basel). 2022 Dec 12;14(24):6127. doi: 10.3390/cancers14246127.
4
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).一线奥希替尼治疗体力状态不佳和 EGFR 突变阳性非小细胞肺癌患者的 II 期研究的理由和方案设计(OPEN/TORG2040)。
BMC Cancer. 2022 Dec 15;22(1):1314. doi: 10.1186/s12885-022-10409-6.
5
Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab.中性粒细胞与淋巴细胞比值(NLR)升高与不可切除 III 期 NSCLC 患者接受巩固性 durvalumab 治疗后无进展生存期较差相关。
Thorac Cancer. 2022 Nov;13(21):3058-3062. doi: 10.1111/1759-7714.14646. Epub 2022 Sep 16.
6
Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review.血清淀粉样蛋白A在癌症预后中的作用:一项荟萃分析和系统评价
Transl Cancer Res. 2021 May;10(5):2255-2264. doi: 10.21037/tcr-20-3417.
7
Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies - State of the Art.全身炎症反应在女性生殖器官恶性肿瘤中的作用——最新进展
Cancer Manag Res. 2021 Jul 9;13:5491-5508. doi: 10.2147/CMAR.S312828. eCollection 2021.
8
Prognostic impact of maximum standardized uptake value on F-FDG PET/CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study.最大标准化摄取值对晚期非小细胞肺癌原发肺病灶 F-FDG PET/CT 显像生存预后的影响:一项回顾性研究。
Thorac Cancer. 2021 Mar;12(6):845-853. doi: 10.1111/1759-7714.13863. Epub 2021 Jan 29.
9
Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis.贝伐单抗用于治疗非小细胞肺癌脑转移患者:一项荟萃分析。
Open Med (Wars). 2020 Jul 1;15(1):589-597. doi: 10.1515/med-2020-0192. eCollection 2020.
10
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.中国肺癌患者的全面基因组特征和对厄洛替尼/吉非替尼耐药个体的突变特征。
Sci Rep. 2020 Nov 20;10(1):20243. doi: 10.1038/s41598-020-76791-y.